---
layout: default
title: Venetoclax
parent: 僅模型預測 (L5)
nav_order: 659
evidence_level: L5
indication_count: 10
---

# Venetoclax
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Venetoclax: From Chronic Lymphocytic Leukemia to CLL/SLL with IGHV Somatic Hypermutation

## One-Sentence Summary

Venetoclax is a selective BCL-2 inhibitor internationally established for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia; no original-indication or licensing data for this drug currently exists in the Saudi Arabia regulatory file (drug not marketed). The TxGNN model's top-ranked prediction is **CLL/SLL with IGHV somatic hypermutation**, a highly specific molecular subtype of CLL, but **no clinical trials or publications specific to this subtype** were found in this evidence pack — the signal is a model-score extrapolation from the already-recognized parent indication (CLL/SLL) rather than new empirical evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Chronic Lymphocytic Leukemia (CLL) — internationally established indication for venetoclax; no Saudi Arabia licensing record exists in this data pack (drug not marketed) |
| Predicted New Indication | Chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene (IGHV) somatic hypermutation |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L5 (no clinical trial or literature record specific to this molecular subtype) |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data for this record is not available (marked as a data gap, DG002). Based on known pharmacological information, venetoclax is a selective, orally bioavailable small-molecule inhibitor of the anti-apoptotic protein BCL-2. Its efficacy in chronic lymphocytic leukemia is internationally established — CLL/SLL cells frequently overexpress BCL-2 to evade apoptosis, and venetoclax-based regimens (e.g., venetoclax-rituximab) have demonstrated superior progression-free and overall survival versus chemoimmunotherapy in randomized trials such as MURANO.

The TxGNN-predicted node here, however, is not simply "CLL/SLL" — it is a narrower, molecularly-defined subtype based on IGHV somatic hypermutation status. IGHV mutation status is a well-recognized prognostic biomarker in CLL that influences treatment response, so a subtype-specific validation would, in principle, still carry clinical value. In practice, this evidence pack found **zero clinical trials and zero publications** matching this exact subtype label. The most relevant supporting trial identified in the underlying dataset (MURANO, PMID 40009494) was retrieved under a different, unrelated candidate node (Hodgkin lymphoma) in this same pack — itself a sign of ontology/retrieval mismatch rather than direct subtype evidence.

In short: the mechanistic rationale (BCL-2 dependency in CLL/SLL) is sound at the parent-indication level, but the specific IGHV-hypermutation subtype prediction is currently an extrapolation without dedicated confirmatory data.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Saudi Arabia Market Information

Venetoclax is not currently marketed in Saudi Arabia; no registered product authorizations, brand names, or dosage forms are on file (0 licenses recorded).

---

## Cytotoxicity

Venetoclax is an antineoplastic agent (approved internationally for hematologic malignancies including CLL/SLL and AML), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy — selective BCL-2 inhibitor (not a conventional cytotoxic chemotherapy agent) |
| Myelosuppression Risk | High — neutropenia (including febrile neutropenia) and thrombocytopenia are well-documented, dose-related adverse effects in venetoclax registrational trials |
| Emetogenicity Classification | Low — oral targeted agent; gastrointestinal effects (diarrhea, nausea) are more common than emesis |
| Monitoring Items | CBC with differential (especially during dose ramp-up), renal function, electrolytes and uric acid (tumor lysis syndrome risk), liver function |
| Handling Protection | Tumor lysis syndrome (TLS) is venetoclax's signature safety concern, particularly during the initial dose ramp-up; TLS prophylaxis and staged dosing per international labeling is required. Local (Saudi) package insert precautions are not yet available since the product is not marketed there |

---

## Safety Considerations

Please refer to the package insert for safety information. (Local key warnings, contraindications, and drug-interaction data are not currently available in this evidence pack — flagged as a Blocking data gap, DG001.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
While venetoclax's BCL-2-inhibition mechanism is well-supported for CLL/SLL broadly, the specific IGHV-somatic-hypermutation subtype prediction has no direct clinical trial or literature evidence in this pack — it is a model-driven extrapolation from the parent indication rather than an independently validated repurposing signal. Proceeding further is not warranted until subtype-specific data is confirmed.

**To proceed, the following is needed:**
- TFDA/SFDA package insert (warnings, contraindications) — currently a Blocking gap (DG001)
- Confirmed drug mechanism-of-action record from DrugBank — currently a High-severity gap (DG002)
- Confirmation of venetoclax's original approved indications and any Saudi Arabia registration pathway status
- A targeted literature/trial search specifically for IGHV-mutation-stratified venetoclax outcomes in CLL/SLL

*Note: This evidence pack also scores nine other candidate indications for venetoclax (ranks 2–10), ranging from strong, standard-of-care-level evidence (e.g., myeloid leukemia, L1) to isolated model predictions with no supporting data (e.g., malignant spiradenoma, L5). Those are outside the scope of this report, which addresses only the top-ranked prediction per evaluation protocol.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

